Publikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (1)

2021

  1. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394